ALIFE reported a net profit of Rs 1.31 billion, reflecting a decline from the previous year
Filed as: Financial Results for the Year Ended December 31, 2025
Summary
ALIFE reported a net profit of Rs 1.31 billion, reflecting a decline from the previous year, while total assets increased to Rs 134.59 billion.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | 36412679 | 30986830 | +17.5% |
| Net profit | 1314311 | 1554305 | -15.4% |
| Total Assets | 134592532 | 116444949 | +15.6% |
| Total Equity | 6334002 | 5432729 | +16.6% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue rose to Rs 36.41 billion from Rs 30.99 billion, up 17.8%.
- Net income decreased to Rs 21.04 billion from Rs 26.71 billion, a decline of 21.1%.
- Total assets increased to Rs 134.59 billion from Rs 116.44 billion, reflecting a growth of 15.6%.
Adamjee Life Assurance Company Limited (ALIFE) on Nafa
Last price Rs 30.04 · Insurance · You can own ALIFE shares from your phone.
More ALIFE announcements
- NoticeTransmission of Quarterly Report for the Period Ended September 30, 2026
- Financial resultAdamjee Life Assurance Company Limited reported a decline in net profit to Rs 549 million for the nine months ended September 30Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting
- NoticeCredit of Interim Cash Dividend - Q2 2026
- NoticeNewspaper Publications - Declaration of Interim Dividend & Book Closure Notice
- NoticeNOTICE TO THE SHAREHOLDERS TO FILE CLAIM FOR UNCLAIMED DIVIDEND (D-1)
Source: Adamjee Life Assurance Company Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.